3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
padeliporfin
5
Nivolumab
5
Ipilimumab
4
Sunitinib
3
Specimen Handling
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Abiraterone Acetate
3
pembrolizumab
2
motexafin gadolinium
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
abiraterone
2
Surveys and Questionnaires
2
Radiation Dose Hypofractionation
2
Pluvicto
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
CTLA-4 Antigen
2
vinflunine
1
valrubicin
1
tislelizumab
1
temsirolimus
1
sipuleucel-T
1
relatlimab
1
palladium-bacteriopheophorbide
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Tinzaparin
×
Genitourinary
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled